Principles of Weight-Based Ketamine Dosing
Weight-based dosing is the standard approach for ketamine administration in clinical practice. Expressing doses in milligrams per kilogram (mg/kg) allows clinicians to individualize therapy across a wide range of patient body sizes while maintaining target plasma concentrations within the therapeutic window. However, the simplicity of weight-based calculations belies important nuances related to body composition, the choice of weight metric, and indication-specific dose ranges that clinicians must understand to dose safely and effectively.
The fundamental rationale for weight-based dosing rests on the relationship between body mass, volume of distribution, and drug clearance. For ketamine, a moderately lipophilic agent with a volume of distribution of 3 to 5 L/kg, total body weight correlates reasonably well with drug distribution in patients of normal body composition. A full discussion of ketamine's distribution properties can be found in the pharmacokinetics overview. When body composition deviates significantly from the norm, particularly in obesity, adjustments become necessary.
Dosing Ranges by Indication
Treatment-Resistant Depression
The evidence-based standard for intravenous ketamine in treatment-resistant depression is 0.5 mg/kg infused over 40 minutes. This dose was established in the seminal trials by Berman et al. and Zarate et al., as reviewed in the ketamine for depression literature. and has been replicated across numerous subsequent studies. For a 70 kg patient, this translates to a 35 mg total dose.
Some clinicians employ a dose-titration approach, beginning at 0.3 mg/kg for the initial infusion and increasing to 0.5 mg/kg based on tolerability and response. Doses below 0.1 mg/kg have generally not demonstrated clinically meaningful antidepressant effects in controlled trials. There is limited evidence supporting doses above 0.5 mg/kg for depression, and higher doses increase the risk of dissociative and cardiovascular adverse effects without clear additional benefit.
Acute Pain and Perioperative Analgesia
For acute pain in the emergency department or perioperative setting, bolus doses of 0.1 to 0.35 mg/kg intravenously are typical. The American College of Emergency Physicians (ACEP) guidelines support a dose of 0.3 mg/kg IV administered over 15 minutes as an analgesic alternative or adjunct to opioids.
Continuous infusions for postoperative pain are generally initiated at 0.1 to 0.2 mg/kg/hour, with a maximum commonly cited at 0.3 mg/kg/hour for ward-level care. Higher infusion rates may be used in monitored settings such as the intensive care unit, but these approach subanesthetic doses and require enhanced surveillance.
Chronic Pain Syndromes
Multi-day infusion protocols for chronic pain, particularly complex regional pain syndrome (CRPS) and other neuropathic conditions, employ more aggressive dosing. Protocols vary widely between centers, but a common approach involves starting at 0.1 mg/kg/hour and titrating upward to 0.3 to 0.5 mg/kg/hour over several days. Total daily doses in these protocols may reach 300 to 500 mg, and careful cardiovascular and neuropsychiatric monitoring is mandatory.
Intranasal Dosing
For intranasal administration, including the FDA-approved esketamine product, dosing is typically expressed in fixed milligram amounts rather than weight-based calculations. Esketamine (Spravato) is administered as 56 mg or 84 mg per session. For compounded racemic intranasal ketamine, weight-based doses of 0.5 to 1.0 mg/kg are sometimes used, though standardization is lacking.
Sublingual and Oral Dosing
Sublingual ketamine troches or tablets are commonly prescribed at doses ranging from 0.5 to 2.0 mg/kg, with the higher doses compensating for the lower bioavailability of approximately 25 to 30 percent. Oral liquid formulations are similarly dosed, often at 0.5 to 1.5 mg/kg, recognizing that first-pass metabolism will reduce systemic exposure to approximately 17 to 24 percent of the administered dose.
Ideal Body Weight Versus Total Body Weight
A critical question in weight-based ketamine dosing is which weight metric to use. In patients with normal or near-normal body mass index (BMI of 18.5 to 29.9), total body weight (TBW) is appropriate and consistent with how clinical trials were conducted.
In patients with obesity (BMI greater than 30), dosing based on total body weight may lead to supratherapeutic plasma concentrations because ketamine distributes into lean tissue more readily than adipose tissue, and hepatic clearance does not increase proportionally with total body mass. Several approaches have been proposed.
Ideal Body Weight
Ideal body weight (IBW) can be calculated using standard formulas such as the Devine equation. Using IBW alone may result in underdosing in significantly obese patients because some distribution into adipose tissue does occur.
Adjusted Body Weight
Adjusted body weight (AdjBW) uses a correction factor applied to the difference between TBW and IBW. A commonly used formula is AdjBW = IBW + 0.4 multiplied by the quantity (TBW minus IBW). This approach provides a pragmatic middle ground and is recommended by several institutional protocols for ketamine dosing in obese patients.
Clinicians should document which weight metric was used for dose calculation and should exercise heightened vigilance for both reduced efficacy (if IBW alone is used in very obese patients) and excess sedation or hemodynamic effects (if TBW is used in the same population).
Special Population Considerations
Elderly Patients
Patients over 65 years of age may have reduced hepatic blood flow and decreased lean body mass. A conservative starting dose of 0.3 mg/kg IV for depression or 0.1 mg/kg IV bolus for analgesia is prudent, with slower titration. Elderly patients are also more susceptible to ketamine-induced hemodynamic changes and confusion.
Hepatic Impairment
Because ketamine undergoes extensive hepatic metabolism, patients with significant liver disease (Child-Pugh class B or C) may experience prolonged drug exposure. Dose reduction of 25 to 50 percent and extended monitoring intervals are advisable.
Pediatric Patients
While pediatric dosing is beyond the primary scope of low-dose adult ketamine therapy, it is worth noting that children generally have higher weight-normalized clearance rates and may require relatively higher mg/kg doses to achieve equivalent plasma concentrations. Pediatric analgesic doses of 0.1 to 0.3 mg/kg IV are commonly used in emergency and perioperative settings.
Practical Calculation Examples
For clinical utility, consider a standard calculation for a 70 kg adult receiving IV ketamine for depression: 0.5 mg/kg multiplied by 70 kg equals 35 mg, to be infused over 40 minutes. For an 110 kg patient with a BMI of 38, using adjusted body weight with IBW of 75 kg yields AdjBW = 75 + 0.4(110 - 75) = 89 kg, and the dose would be 0.5 mg/kg multiplied by 89 kg, equaling 44.5 mg, which might be rounded to 45 mg for practical preparation.
Clinicians are encouraged to use standardized dose calculation tools and to verify all calculations independently before administration. Weight-based dosing is a starting framework, not a substitute for clinical judgment, and individual patient responses should always guide subsequent dose adjustments.
References
- MedlinePlus: Ketamine Injection Drug Information — National Library of Medicine patient medication information including weight-based dosing guidance
- PubMed: Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics — Pharmacokinetic review including body weight considerations and dose calculations
- DailyMed: FDA Drug Label Information — National Library of Medicine database for official FDA drug labeling with approved dose ranges
- ASA: American Society of Anesthesiologists — Professional society providing weight-based dosing standards for anesthetic and sub-anesthetic ketamine use
Share